ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VLG Venture Life Group Plc

39.00
-0.50 (-1.27%)
22 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -1.27% 39.00 38.50 39.50 39.50 38.50 39.50 335,898 15:55:36
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Misc Retail Stores, Nec 43.98M 520k 0.0041 95.12 49.07M
Venture Life Group Plc is listed in the Misc Retail Stores sector of the London Stock Exchange with ticker VLG. The last closing price for Venture Life was 39.50p. Over the last year, Venture Life shares have traded in a share price range of 27.00p to 42.50p.

Venture Life currently has 125,831,530 shares in issue. The market capitalisation of Venture Life is £49.07 million. Venture Life has a price to earnings ratio (PE ratio) of 95.12.

Venture Life Share Discussion Threads

Showing 18676 to 18696 of 36725 messages
Chat Pages: Latest  749  748  747  746  745  744  743  742  741  740  739  738  Older
DateSubjectAuthorDiscuss
28/4/2018
23:58
To become successful trading binary options requires a lot of hard work, practice, dedication and determination to become an independent trader. Find out how my team of professionals make thousands weekly. Email: lifeofpiotr@gmail.com
lifeofpiotr
28/4/2018
21:06
Google does like its moon shot spending thats for sure.

I like the liquid assets available. Lowers true PE by quite a chunk.

Ultimate company would be a merger of amazon (JB) and alphabet.

Quite possibly would be too powwrful.

thelongandtheshortandthetall
28/4/2018
18:56
Flag:
NTQ is frisky and its results are mid June.
apad

apad
28/4/2018
18:43
Thanks APAD - as usual, a unique and interesting viewpoint
hydrus
28/4/2018
18:38
No, Hydrus, I don't pay for TW articles.
I approve of his campaigning and he provides data to justify his point of view.
I assume his style is advertising and it doesn't bother me one way or another.
"Walk between the raindrops, smooth as a pearl"
He did organise an Investor Show where I saw the CEO of FFX make a dragon's den presentation. However, the tips and comments on the site are painfully trivial.

On recommendations, I rate Paul Scott and tried to make a donation once, but it wanted too much personal data.

Yup. Very interesting insight, Iomax. Ta.

bamboo, FARN is so little traded I'm not sure what one can deduce from the chart.
"If the drug is near 100% certain, isn't this mostly in the price already?"
The efficient market theory - Yeah Right!

apad😎

apad
28/4/2018
17:28
Thanks Iomax useful to see. Got in AMZN at circa 550p. Fair bit behind Mod. Still annoyed I didn't invest back in the early 2000's when I was using their services. Fun fact - it's been a 100 bagger twice. Once in the tech boom and then again post 2000.
hydrus
28/4/2018
17:24
I am happy with my holding in Amazon,and tempted to add. The FT’s Lex column highlights the growth in their advertising revenues. It surmises that most of the c. $2bn of the “other” revenue line in their recently quarterly results was advertising, that this had doubled year on year, and was likely to reach c. $10bn for the full year. Even then that will be only half AWS’s size. Great to have two decent, fast growing, revenue stream’s with fatter margins than core ecommerce.
lomax99
28/4/2018
17:11
On Woodford* ........Afternoon drinking is bad for brain cells
hydrus
28/4/2018
17:07
APAD do you pay for winniforth's articles or just get a the free ones?He may be right on Winniforth but I find his aggressive style unpalatable and wouldn't want to give him a penny.
hydrus
28/4/2018
16:35
Re farn, thanks for the reply and mod for the info.
If the drug is near 100% certain, isn't this mostly in the price already?

The chart looks rangebound. There are some potential turns that could indicate activity in the chart. 11-15/5/2018, and 4/6/2018. Watch prior trend for direction, if any.

bamboo2
28/4/2018
16:30
I've never understood the way google spends so-called R&D money, Hydrus.
Just looks like a playground.

Winnifroth's revelations about Woodford are shocking.

FARN FY 8 May.

apad

apad
28/4/2018
16:15
I've been looking at google and amazon and the difference in the rating between the two, to see if google is genuinely cheap. My conclusion is that google is chucking R&D money left, right and centre with no strategy and certainly no clear commercial payback. Amazon is focussed and efficient and is spending money sensibly. The difference between the two is Jeff Bezos. A brilliant CEO who is an owner is a critical part of the jigsaw puzzle.I'm up 18.5% this year following >100% last year. Poor old woody Woodford needs to look at this thread a bit more.
hydrus
28/4/2018
12:43
Those were the days, mod! 266p my first purchase
These purchases testify to my FARN addiction.
apad😊

FARN 9-Jan-2017
FARN 17-Jan-2017
FARN 24-Apr-2017
FARN 9-May-2017
FARN 11-Jul-2017
FARN 26-Oct-2017
FARN 2-Nov-2017
FARN 2-Nov-2017
FARN 13-Nov-2017
FARN 14-Nov-2017
FARN 14-Nov-2017
FARN 18-Dec-2017
FARN 19-Dec-2017
FARN 21-Dec-2017
FARN 29-Dec-2017
FARN 24-Apr-2018
FARN 24-Apr-2018
FARN 24-Apr-2018
FARN 26-Apr-2018

apad
28/4/2018
10:51
Apad, it's worthwhile noting that most of us including you dipped our toes in at around 270, my average entry is below 350, early stage pharma is either a multibag or almost nothing, but can be accommodated as a part of PF risk management, if you allocate a small amount to it, but it depends highly on individuals personal circumstances. I have 2 early stage pharma, FARN and DNL, both very high risk imo.
modform
28/4/2018
10:11
"Thanks apad, is it 100% certain?" & Big7.

The Phase II trial results were overwhelming and it was a close run thing as to whether approval would be granted straightaway.
In my view the Phase III's main task is to differentiate types of patients.
It is authorised for use in extreme (I forget the official term) cases.
Company raised money at 805p to start manufacturing facilities.

I think decimate is a mild term for what would happen if the trial failed, Big7.

apad😊

apad
28/4/2018
10:01
APAD re 18598 I think I am a contrarian investor. Unusual I have found is profitable
When a shr/sector is unloved it can be an absolute bargain. When it's a dead cert, or everyone seems to be buying - that's the time to be thinking of selling in my experience hence my previous question
My timing isn't the best but I prefer to think of it as ahead of the crowd

big7ime
28/4/2018
09:38
APAD I don't follow FARN and know nothing about it but how can you be so certain? And isn't that rather dangerous if (as is often the case with pharm cos) they do not get the result people are expecting!? Wouldn't it decimate the sp
big7ime
28/4/2018
09:20
cbootle re BAB, it was attacked by shorters but I think those positions are unwinding. Liberum has a £11 target and RBC £10
robow
28/4/2018
09:17
I average a 90% - 98% success win rate using IQoption and 24option. You can feel free to join my team of professionals. DM- lifeofpiotr@gmail
lifeofpiotr
28/4/2018
09:03
janeann, I missed acso as I was concentrating on other positions. A poor excuse.

Have just had my second best ever week, with p/f now up approx 18% ytd :-)

Superbly timed trade [thanks to apexes] in SPE, Quick one with KWS [approx. 7%] and a long awaited breakout for WAND. Like others here I took profit on ZOO, as I am worried by the potential for a H&S pattern. Will post a chart if it looks like it might confirm as a valid pattern.

Thanks apad, is it 100% certain? Will look at chart later.

============================================

edit, janeann, re acso, I just looked at my day planner and realised the reason that I decided not to go for acso was that while the mid price based chart had the turn on Thursday, my last market price based chart had a turn for this Monday 30 April, and I was concerned about a reversal.

bamboo2
28/4/2018
08:36
bamboo
FARN
Certainty of Phase III approval of a unique drug based on a unique mechanism. No other treatment for ARDS.
Already setting up manufacturing.
Becoming a pharma company not licensing.

Useful inside info cbootle.
apad

apad
Chat Pages: Latest  749  748  747  746  745  744  743  742  741  740  739  738  Older